S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
S&P 500   4,986.30 (-0.50%)
DOW   37,923.01 (+0.39%)
QQQ   418.52 (-1.15%)
AAPL   165.02 (-1.21%)
MSFT   401.42 (-0.70%)
META   487.91 (-2.77%)
GOOGL   154.64 (-0.88%)
AMZN   176.10 (-1.74%)
TSLA   149.52 (-0.27%)
NVDA   821.64 (-2.96%)
AMD   149.78 (-3.42%)
NIO   3.86 (-3.50%)
BABA   68.86 (-0.03%)
T   16.34 (+0.06%)
F   12.12 (+0.50%)
MU   107.92 (-3.58%)
GE   150.69 (-1.47%)
CGC   8.04 (+2.68%)
DIS   111.69 (-0.66%)
AMC   3.19 (+9.25%)
PFE   25.81 (+1.65%)
PYPL   62.05 (-0.08%)
XOM   120.04 (+1.28%)
Free Trial

Ocular Therapeutix (OCUL) Stock Forecast & Price Target

→ Biden’s $374B Giveaway Into This Sector (From DTI) (Ad)
Free ocul Stock Alerts
$5.26
-0.60 (-10.24%)
(As of 11:40 AM ET)
Compare
Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability

Ocular Therapeutix Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$17.60
234.60% Upside
High Forecast$24.00
Average Forecast$17.60
Low Forecast$15.00
TypeCurrent Forecast
4/20/23 to 4/19/24		1 Month Ago
3/21/23 to 3/20/24		3 Months Ago
1/20/23 to 1/20/24		1 Year Ago
4/20/22 to 4/20/23
Consensus Rating
Buy
Buy
Buy
Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
1 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
0 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$17.60$16.80$14.00$12.80
Predicted Upside234.60% Upside145.61% Upside226.91% Upside154.70% Upside
Get Ocular Therapeutix Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.

OCUL Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

OCUL Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Ocular Therapeutix Stock vs. The Competition

TypeOcular TherapeutixMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside186.69% Upside928.01% Upside12.31% Upside
News Sentiment RatingPositive News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/19/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$16.00+173.04%
4/16/2024JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingMarket Outperform ➝ Market Outperform$24.00+206.91%
2/26/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetOverweight ➝ Overweight$10.00 ➝ $15.00+45.07%
2/9/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$15.00+198.21%
9/14/2023Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOutperform ➝ Outperform$18.00+390.46%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 11:53 AM ET.

OCUL Price Target - Frequently Asked Questions

What is Ocular Therapeutix's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Ocular Therapeutix stock is Buy based on the current 5 buy ratings for OCUL. The average twelve-month price prediction for Ocular Therapeutix is $17.60 with a high price target of $24.00 and a low price target of $15.00. Learn more on OCUL's analyst rating history.

Do Wall Street analysts like Ocular Therapeutix more than its competitors?

Analysts like Ocular Therapeutix more than other Medical companies. The consensus rating for Ocular Therapeutix is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how OCUL compares to other companies.

Does Ocular Therapeutix's stock price have much upside?

According to analysts, Ocular Therapeutix's stock has a predicted upside of 168.95% based on their 12-month stock forecasts.

What analysts cover Ocular Therapeutix?

Ocular Therapeutix has been rated by Bank of America, HC Wainwright, JMP Securities, and Piper Sandler in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NASDAQ:OCUL) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Biden’s $374B Giveaway Into This Sector
DTI
The #1 Crypto for 2024
InvestorPlace
Did You Get Your Free Bitcoin Yet?
Crypto Swap Profits
Urgent alert: open this for a huge profit potential
Timothy Sykes
1970’s computer coder issues shocking A.I. warning
TradeSmith
Top 5 AI Stocks to Buy for 2024
Market Moving Trends